Phosphorylation of ERK-Dependent NF-κB Triggers NLRP3 Inflammasome Mediated by Vimentin in EV71-Infected Glioblastoma Cells.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
29 Jun 2022
Historique:
received: 25 05 2022
revised: 17 06 2022
accepted: 27 06 2022
entrez: 9 7 2022
pubmed: 10 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Enterovirus 71 (EV71) is a dominant pathogenic agent that may cause severe central nervous system (CNS) diseases among infants and young children in the Asia-pacific. The inflammasome is closely implicated in EV71-induced CNS injuries through a series of signaling pathways. However, the activation pathway of NLRP3 inflammasome involved in EV71-mediated CNS injuries remains poorly defined. In the studies, EV71 infection, ERK1/2 phosphorylation, and activation of NLRP3 are abolished in glioblastoma cells with low vimentin expression by CRISPR/Cas9-mediated knockdown. PD098059, an inhibitor of p-ERK, remarkably blocks the vimentin-mediated ERK1/2 phosphorylation in EV71-infected cells. Nuclear translocation of NF-κB p65 is dependent on p-ERK in a time-dependent manner. Moreover, NLRP3 activation and caspase-1 production are limited in EV71-infected cells upon the caffeic acid phenethyl ester (CAPE) administration, an inhibitor of NF-κB, which contributes to the inflammasome regulation. In conclusion, these results suggest that EV71-mediated NLRP3 inflammasome could be activated via the VIM-ERK-NF-κB pathway, and the treatment of the dephosphorylation of ERK and NF-κB inhibitors is beneficial to host defense in EV71-infected CNS.

Identifiants

pubmed: 35807435
pii: molecules27134190
doi: 10.3390/molecules27134190
pmc: PMC9268588
pii:
doi:

Substances chimiques

Inflammasomes 0
NF-kappa B 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
NLRP3 protein, human 0
VIM protein, human 0
Vimentin 0
Mitogen-Activated Protein Kinase 1 EC 2.7.11.24
Mitogen-Activated Protein Kinase 3 EC 2.7.11.24

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : The Basic Research Project of Key Laboratory of Guangzhou,China
ID : 202102100001
Organisme : Grant from School of Public Health of SoutheZrn Medical University, China
ID : GW202116

Références

Microbes Infect. 2010 Jul;12(7):505-10
pubmed: 20348010
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
Cell Rep. 2015 Jul 7;12(1):42-48
pubmed: 26119741
PLoS Pathog. 2017 Jan 6;13(1):e1006123
pubmed: 28060938
PLoS One. 2012;7(3):e32405
pubmed: 22479324
Nat Rev Urol. 2017 May;14(5):284-295
pubmed: 28266511
Neuron. 2005 Mar 3;45(5):715-26
pubmed: 15748847
PLoS One. 2013 Sep 20;8(9):e73900
pubmed: 24073199
Rev Med Virol. 2015 Mar;25(2):115-28
pubmed: 25704797
Pharmacol Rep. 2017 Oct;69(5):1030-1035
pubmed: 28958612
Int Immunopharmacol. 2018 Jul;60:111-120
pubmed: 29730555
Cell Signal. 2010 Feb;22(2):234-46
pubmed: 19800403
Clin Exp Vaccine Res. 2017 Jan;6(1):4-14
pubmed: 28168168
Neurosci Lett. 2017 May 10;649:100-106
pubmed: 28392360
Front Immunol. 2020 Oct 05;11:551449
pubmed: 33123130
Neurocrit Care. 2017 Aug;27(1):44-50
pubmed: 28181102
Virol Sin. 2012 Aug;27(4):254-8
pubmed: 22899434
Front Immunol. 2018 May 04;9:983
pubmed: 29780394
Annu Rev Cell Dev Biol. 2012;28:137-61
pubmed: 22974247
Brain. 2017 Sep 1;140(9):2273-2285
pubmed: 29050380
Lancet Infect Dis. 2010 Nov;10(11):778-90
pubmed: 20961813
Int Rev Immunol. 2018 Jan 2;37(1):57-68
pubmed: 28961037
Front Immunol. 2016 Dec 05;7:540
pubmed: 27994587
Curr Treat Options Neurol. 2017 May;19(5):19
pubmed: 28417344
N Engl J Med. 2014 Feb 27;370(9):792-4
pubmed: 24571750
Cell Signal. 2006 Jul;18(7):994-1005
pubmed: 16242916
J Hematol Oncol. 2016 Nov 14;9(1):122
pubmed: 27842563
Sci Rep. 2016 Dec 14;6:39303
pubmed: 27966632
Nat Commun. 2015 Mar 12;6:6574
pubmed: 25762200
J Neurosci. 2010 Nov 24;30(47):15811-20
pubmed: 21106820
J Microbiol Immunol Infect. 2000 Dec;33(4):205-16
pubmed: 11269363
Lancet Infect Dis. 2014 Apr;14(4):308-318
pubmed: 24485991
Virol J. 2017 Jan 11;14(1):2
pubmed: 28081706
J Virol. 2014 May;88(10):5816-33
pubmed: 24623428
J Virol. 2017 Jun 9;91(13):
pubmed: 28424281
FEMS Microbiol Rev. 2002 Mar;26(1):91-107
pubmed: 12007645
Viruses. 2015 Mar 20;7(3):1344-56
pubmed: 25803100
Viruses. 2015 Dec 14;7(12):6613-30
pubmed: 26694447

Auteurs

Zelong Gong (Z)

Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Microbiology, School of Public Health, Southern Medical University, Guangzhou 510515, China.

Xuefeng Gao (X)

Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Microbiology, School of Public Health, Southern Medical University, Guangzhou 510515, China.

Qingqing Yang (Q)

Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Microbiology, School of Public Health, Southern Medical University, Guangzhou 510515, China.

Jingxian Lun (J)

Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Microbiology, School of Public Health, Southern Medical University, Guangzhou 510515, China.

Hansen Xiao (H)

Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Microbiology, School of Public Health, Southern Medical University, Guangzhou 510515, China.

Jiayu Zhong (J)

Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Microbiology, School of Public Health, Southern Medical University, Guangzhou 510515, China.
Center Laboratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510120, China.

Hong Cao (H)

Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Microbiology, School of Public Health, Southern Medical University, Guangzhou 510515, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH